ORN Stock Overview
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.87 |
| 52 Week High | €2.26 |
| 52 Week Low | €1.58 |
| Beta | 0.64 |
| 1 Month Change | 7.60% |
| 3 Month Change | -2.40% |
| 1 Year Change | -11.68% |
| 3 Year Change | -47.08% |
| 5 Year Change | -49.17% |
| Change since IPO | -26.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -5.1% | -2.0% |
| 1Y | -11.7% | -21.1% | -0.3% |
Return vs Industry: ORN exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: ORN underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| ORN volatility | |
|---|---|
| ORN Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ORN has not had significant price volatility in the past 3 months.
Volatility Over Time: ORN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 43 | Carlos Manuel Arjol | www.oryzon.com |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
| ORN fundamental statistics | |
|---|---|
| Market cap | €114.08m |
| Earnings (TTM) | -€3.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-32.8x
P/E RatioIs ORN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.71m |
| Earnings | -US$3.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.064 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 24.8% |
How did ORN perform over the long term?
See historical performance and comparison